Oncotarget · 2014 · 44 citations · 38 references
MedicineCell BiologyHematologyCell ProliferationChemotherapyHematologic OncologyHematologic MalignanciesHematologic Malignancy TherapyHematopoietic NeoplasmsLymphoid NeoplasmsMinimal Residual DiseaseBone Marrow - Derived CellsBone Marrow Mesenchymal Stem CellsBone Marrow-derived Mesenchymal Stromal CellsChronic Lymphocytic Leukemia TherapyLymphoid Organ Stromal CellsPrimary CellsSecondary Lymphoid TissueZap-70 Activation
// Noelia Purroy 1 , Pau Abrisqueta 1 , Júlia Carabia 1 , Cecilia Carpio 1 , Carles Palacio 1 , Francesc Bosch 1,* and Marta Crespo 1,* 1 Laboratory of Experimental Hematology, Department of Hematology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain * These authors contributed equally to this work Correspondence: Marta Crespo, email: // Keywords : CLL, co-culture, proliferation, immunophenotype, chemoresistance, ZAP-70 Received : September 19, 2014 Accepted : December 02, 2014 Published : December 03, 2014 Abstract Chronic lymphocytic leukemia (CLL) cells residing in the bone marrow (BM) and in secondary lymphoid tissues receive survival and proliferative signals from the microenvironment, resulting in persistence of residual disease after treatment. In this study, we characterized primary CLL cells cultured with BM stromal cells, CD40 ligand and CpG ODN to partially mimic the microenvironment in the proliferative centers. This co-culture system induced proliferation and chemoresistance in primary CLL cells. Importantly, co-cultured primary CLL cells shared many phenotypical features with circulating proliferative CLL cells, such as upregulation of ZAP-70 and CD38 and higher CD49d and CD62L expression. This indicates aggressiveness and capability to interact with surrounding cells, respectively. In addition, levels of CXCR4 were decreased due to CXCR4 internalization after CXCL12 stimulation by BM stromal cells. We suggest that this co-culture system can be used to test drugs and their combinations that target the proliferative and drug resistant CLL cells.
38
Daniel F. Legler, Marcel Loetscher, Regula Stuber Roos et al. · The Journal of Experimental Medicine · 1998 · 850 citations · Full text